Contineum announces FDA authorization for PIPE-791

Contineum (CTNM) announced authorization of its investigational new drug, or IND, application from FDA for PIPE-791 for the treatment of chronic pain associated with two separate indications, osteoarthritis, or OA, and low back pain, or LBP. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor. The exploratory Phase 1b, randomized, double-blind, placebo-controlled, crossover, multi-center study is expected to begin in the first quarter of 2025. The company expects to enroll approximately 40 patients at up to five sites, and a treatment duration of 28 days. Contineum anticipates topline data from the PIPE-791 Phase 1b chronic pain study in early 2026.